The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
GSK and Flagship to jointly fund up to $150 million upfront
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated
